Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 7/20 | 0.41 |
| ▸ | MCL1 | Q07820 | 7/20 | 0.41 |
| ▸ | BCL2 | P10415 | 6/20 | 0.41 |
| ▸ | FABP3 | P05413 | 1/20 | 0.40 |
| ▸ | FABP4 | P15090 | 1/20 | 0.40 |
| ▸ | CCKAR | P32238 | 5/20 | 0.39 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.38 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | RPA1 | P27694 | 1/20 | 0.37 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.37 |
| ▸ | GCGR | P47871 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5148944 | 0.93 | FABP4 (0.43) | MDM2MCL1BCL2FABP3FABP4 | |
| SCHEMBL5152083 | 0.92 | MDM2 (0.39) | MDM2MCL1BCL2FABP3FABP4 | |
| SCHEMBL5148624 | 0.91 | CCKAR (0.47) | MDM2MCL1BCL2FABP3FABP4 | |
| SCHEMBL5148724 | 0.89 | BCL2 (0.45) | MDM2MCL1BCL2FABP3FABP4 | |
| SCHEMBL5148880 | 0.89 | MDM2 (0.41) | MDM2MCL1BCL2FABP3FABP4 | |
| SCHEMBL5151975 | 0.89 | CA12 (0.41) | MDM2MCL1BCL2NR3C1PIK3CA | |
| SCHEMBL5148760 | 0.88 | FABP3 (0.39) | MDM2MCL1BCL2FABP3FABP4 | |
| SCHEMBL5148732 | 0.87 | MDM2 (0.40) | MDM2MCL1BCL2FABP3FABP4 | |
| SCHEMBL5171475 | 0.86 | RPA1 (0.42) | MDM2MCL1BCL2FABP3FABP4 | |
| SCHEMBL5148783 | 0.86 | PTGS2 (0.41) | FABP3FABP4PIK3CAPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1567503-B1 | PYRAZOLE DERIVATIVES USEFUL AS COX-I INHIBITORS | ASTELLAS PHARMA INC (JP) | 2011-12-21 | — | — | EP | disclosed |
| US-20070112037-A1 | Pyrazole Derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2007-05-17 | — | — | US | disclosed |
| US-7183306-B2 | Pyrazole derivatives | ASTELLAS PHARMA INC. (JP) | 2007-02-27 | — | — | US | disclosed |
| US-20040116475-A1 | Pyrazole derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070112037-A1 | Pyrazole Derivatives | CYP11B2, CYP11B1, CYP3A43 | MDM2 1492/4885MCL1 1748/4885BCL2 2334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.